• <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置首页>技术资料首页>行业动态>公司动态>罗氏公司在新加坡设立新的医学研究中心

    罗氏公司在新加坡设立新的医学研究中心

    Roche2010年1月28日 14:23 点击:3675

    瑞士罗氏Roche
    罗氏公司在新加坡设立新的医学研究中心
     

    Basel, 28 January 2010

    Roche新闻稿
    Roche establishes new medical research hub in Singapore

    Unique public private partnership to accelerate progress in personalising healthcare

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will enter into a strategic alliance with Singapore’s scientific and medical institutions to set up a major new translational research hub in Singapore.

    This “Hub for Translational Medicine” aims to enhance the understanding of how scientific advances from preclinical research can be transferred in practice to patients. Bringing together world-class expertise from Singapore’s scientific and medical research institutions with Roche’s significant capability in translational medicine and clinical development, this new centre will focus on expanding knowledge of disease biology to develop new personalised treatment approaches.

    With an investment of 100 million Swiss Francs, the Hub for Translational Medicine will initially employ around 30 leading scientists. A joint steering committee consisting of members from Roche and the Singapore institutes will define the strategic direction of the alliance and oversee its research projects.

    “Singapore’s research institutions offer outstanding scientific excellence combined with state-of-the-art translational medicine facilities,” said Jean-Jacques Garaud, Global Head of Roche Pharma Research and Early Development. “The powerful combination of intellectual and technological capabilities together with outstanding government commitment at the heart of this collaboration will provide a unique opportunity to drive personalised healthcare.”

    “We are delighted that Roche has chosen to work with Singapore in this pioneering public-private partnership that leverages on our network of biomedical sciences research institutes and academic medical centres. This collaboration will enable Roche to conduct multidisciplinary studies and generate important insights in disease biology to accelerate the drug discovery and development process,” said Dr Beh Swan Gin, Managing Director, Singapore Economic Development Board.

    The Roche-Singapore Hub for Translational Medicine has the potential of setting new standards in developing strategies for drug development and personalizing healthcare. The integrated disciplines and groups are expected to generate benefits for all parties involved and to provide a huge potential for novel scientific expertise and intellectual property to be generated in both therapeutic and diagnostic research and development.

    “Leveraging Singapore’s close-knit research community and clinical research infrastructure, companies are well-positioned to develop cost-effective, efficacious therapies more quickly for Asia and global markets. Within just one decade, Singapore has emerged as a key partner for leading pharmaceutical and biotech companies that seek to accelerate drug discovery in Asia,” said Professor Edward Holmes, Chairman, National Medical Research Council, Singapore.

    “We are proud to partner Roche’s new Hub for Translational Medicine in Singapore. Roche’s decision to collaborate with Singapore’s research institutes attests to the strong core biomedical research capabilities present here and reflects the attractiveness of Singapore as a choice biomedical research hub for impactful industry collaborations.” said Sir George Radda, Chairman, Biomedical Research Council, Agency for Science, Research and Technology (A*STAR), Singapore.

    Scientific and Medical Institutions involved:

    AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR). A*STAR is the lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. A*STAR oversees 14 biomedical sciences, and physical sciences and engineering research institutes, and seven consortia & centres, which are located in Biopolis and Fusionopolis, as well as their immediate vicinity. A*STAR supports Singapore's key economic clusters by providing intellectual, human and industrial capital to its partners in industry. It also supports extramural research in the universities, hospitals, research centres, and with other local and international partners. For more information, please visit A*STAR’s website at http://www.a-star.edu.sg.

    NATIONAL UNIVERSITY OF SINGAPORE (NUS) is a leading research-intensive university centred in Asia. Ranked in the top 30 worldwide, NUS offers a global approach to education and research, with a focus on Asian perspectives and expertise. NUS has three Research Centres of Excellence and 22 university-level research institutes and centres. It also shares a close affiliation with 16 national-level research institutes and centres. Research activities are world class, and NUS is well-known for its research strengths in engineering, life sciences, medicine, social sciences, natural sciences and at the intersection of these disciplines to address issues such as ageing and sustainability. For more information, please visit: www.nus.edu.sg. The Duke-NUS Graduate Medical School Singapore (Duke-NUS) was established in 2005 as a strategic collaboration between the Duke University School of Medicine, located in N. Carolina, USA and the National University of Singapore (NUS). Duke-NUS offers a graduate entry, 4-year medical training programme based on the unique Duke model of education, with one year dedicated to independent study and research projects of a basic science or clinical nature. The first batch of students started term on 1 August 2007. As a player in Singapore’s biomedical community, Duke-NUS has identified five Signature Research Programmes: Cancer & Stem Cell Biology, Neuroscience and Behavioural Disorders, Emerging Infectious Diseases, Cardiovascular & Metabolic Disorders, and Health Services and Systems Research.

    The NATIONAL UNIVERSITY HOSPITAL (NUH) is a tertiary specialist hospital that provides advanced, leading-edge health care. As a university hospital and major referral centre, it also manages two national disease centers, the National University Cancer Institute, Singapore (NCIS) and the National University Heart Centre, Singapore (NUHCS). NUH is unified under a common governance with the NUS Yong Loo Lin School of Medicine, the Faculty of Dentistry and the Alice Lee Center for Nursing Studies as the National University Health System, one of Singapore’s pioneer academic health centers.

    NANYANG TECHNOLOGICAL UNIVERSITY (NTU) is a research intensive university ranked among the top 100 universities. As Singapore’s main science and technology university, NTU makes significant contributions to the nation's renewed drive for research and innovation, with knowledge, expertise and experience in research and development activities relating to science (including biomedical and biotechnological science), engineering and technology.

    NATIONAL HEALTHCARE GROUP (NHG) has more than 9,000 staff and is a leading public healthcare provider in Singapore, renowned for the quality of its medical expertise and facilities, at home and abroad. NHG unites an extensive network of primary healthcare polyclinics, acute and tertiary hospitals and specialty centres to provide holistic yet affordable care to our patients. Together, we bring a rich legacy of over 340 years of medical expertise to our philosophy of patient-centred care. Members of NHG include: Tan Tock Seng Hospital, Institute of Mental Health, National Skin Centre, Johns Hopkins Singapore International Medical Centre, the NHGP chain of nine polyclinics, NHG Eye Institute, and the following business divisions - NHG College, NHG Diagnostics, Primary Care Academy, NHG Health-for-Life, NHG Pharmacy, NHG 1-Health, Singapore Footcare Centre and Energhy.

    SINGAPORE HEALTH SERVICES PTE LTD (SingHealth), Singapore’s largest healthcare provider, is a group of public healthcare institutions that offers integrated, multi-disciplinary medical care, while pursuing cutting-edge research and education to build an Academic Medical Centre with Duke-NUS Graduate Medical School. The group’s key research strengths currently focus on oncology, ophthalmology and cardiology, supported by advanced research facilities. It includes three JCI-accredited hospitals, Singapore General Hospital - Singapore’s flagship and largest tertiary acute hospital and national referral centre, KK Women’s and Children’s Hospital - the country's major tertiary referral centre for women and children, and Changi General Hospital - a regional hospital providing integrated healthcare to residents in the East of the country; (b) the 5 national specialty centres for cancer, heart, eye, neurosciences, and dental care; and (c) a network of primary care clinics.

    About Roche

    Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80’000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

    (来源: Roche )


    全年征稿 / 资讯合作

    联系?#27663;洌簁[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.67994619.com,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权?#20219;?#39064;,请在作品发表之日起一周内与本网联系,否则视为?#29260;?#30456;关权利。


    云南11选5技巧
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    宁夏11选5在线走势图 3dp3试机号 爱彩网比分直墦 上海时时彩软件 篮球什么叫让分胜负 下期平特一肖怎么算 急速赛车彩票官网网址 竞彩篮球大小分结果 2019微信怎么买彩票 大河两码中特 河北快三免费推荐号码 黑龙江时时彩图表10 广东快乐10分80期开什么 民间高手一尾中特平 彩票安徽25选5